HTA Database - Search Results

Sort by Relevance

Search Results [15895 Hits] Selected Records [0 Hits] [Clear]

Year	Source	Title
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Alteplase (Actilyse® Cathflo® 2 mg)
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Saxagliptin (Onglyza®)
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Sodium valproate (Episenta®)
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Collagenase Clostridium histolyticum (Xiapex®)
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Tenofovir disoproxil fumarate (Viread®)
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Histamine dihydrochloride (Ceplene®)
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Sunitinib (Sutent®)
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Ferric carboxymaltose (Ferinject®)
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Valganciclovir (Valcyte®) tablets
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Valganciclovir (Valcyte®) powder for oral solution
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Capecitabine (Xeloda®)
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Tacrolimus (Advagraf®)
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Fentanyl (PecFent®)
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Darunavir (Prezista®)
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Valsartan (Diovan®)
2011	All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG)	Filgrastim (Nivestim®)
2011	Andalusian Health Technology Assessment Area (AETSA)	[Tool to assist in the decision-making of patients susceptible to dialysis]
2011	Andalusian Health Technology Assessment Area (AETSA)	[Patient safety program in pain management units]
2011	Andalusian Health Technology Assessment Area (AETSA)	[Evaluation of surrogate variables in oncology. Advanced and metastatic breast cancer]
2011	Andalusian Health Technology Assessment Area (AETSA)	[Systematic review of the usefulness of the determination of exhaled nitric oxide in the control of infantile and juvenile asthma}
2011	The Swedish Council on Health Technology Assessment (SBU)	[Dabigatran to prevent stroke in patients with atrial fibrillation]
2011	Adelaide Health Technology Assessment (AHTA)	Review of MBS items for specific ophthalmology services under the MBS Quality Framework (Stage I)
2011	Adelaide Health Technology Assessment (AHTA)	Review of interim funded service: vertebroplasty and new review of kyphoplasty
2011	Agency for Healthcare Research and Quality (AHRQ)	Adjunctive devices for patients with acute coronary syndrome undergoing percutaneous coronary intervention
2011	Agency for Healthcare Research and Quality (AHRQ)	Effectiveness of early diagnosis, prevention, and treatment of clostridium difficile infection
2011	Agency for Healthcare Research and Quality (AHRQ)	Second-generation antidepressants in the pharmacologic treatment of adult depression: an update of the 2007 comparative effectiveness review
2011	Agency for Healthcare Research and Quality (AHRQ)	Analgesics for osteoarthritis: an update of the 2006 comparative effectiveness review
2011	Agency for Healthcare Research and Quality (AHRQ)	Attention deficit hyperactivity disorder: effectiveness of treatment in at-risk preschoolers; long-term effectiveness in all ages; and variability in prevalence, diagnosis, and treatment
2011	Agency for Healthcare Research and Quality (AHRQ)	Angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor antagonists (ARBs), and direct renin inhibitors for treating essential hypertension: an update
2011	Blue Cross Blue Shield Association (BCBS)	Transcranial magnetic stimulation for the treatment of schizophrenia
2011	Blue Cross Blue Shield Association (BCBS)	Artificial vertebral disc arthroplasty for treatment of degenerative disease of the cervical spine
2011	Blue Cross Blue Shield Association (BCBS)	Special report: companion diagnostics: example of BRAF gene mutation testing to select patients with melanoma for treatment with BRAF kinase inhibitors
2011	Blue Cross Blue Shield Association (BCBS)	Gene expression profiling as a noninvasive method to monitor for cardiac allograft rejection
2011	Institute for Clinical Evaluative Sciences (ICES)	Health system use by frail Ontario seniors: an in-depth examination of four vulnerable cohorts
2011	Institute for Clinical Evaluative Sciences (ICES)	Ontario stroke evaluation report 2011: improving system efficiency by implementing stroke best practices
2011	Institute for Clinical Evaluative Sciences (ICES)	Registry of the Canadian stroke network - report on the 2008/09 Ontario stroke audit
2011	Institute for Clinical Evaluative Sciences (ICES)	Site-specific rates of shock, therapy and death after ICD implantation in Ontario: report from the Ontario ICD database
2011	Institute for Clinical Evaluative Sciences (ICES)	Uptake of the new fee code for Ontario's enhanced 18-month well baby visit: a preliminary evaluation
2011	Andalusian Health Technology Assessment Area (AETSA)	[Eculizumab (Soliris®) Assessment of effectivity and safety of the drug and economic analysis of use in Paroxysmal Nocturnal Haemoglobinuria therapy]
2011	Health Information and Quality Authority (HIQA)	Health technology assessment of robot-assisted surgery in selected surgical procedures
2011	Institute of Health Economics (IHE)	Fecal transplantation for the treatment of clostridium difficile-associated disease or ulcerative colitis
2011	Institut national d'excellence en sante et en services sociaux (INESSS)	[Computed tomography and its carcinogenic effects in children and youth in Québec]
2011	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Assessment process of the research projects submitted to the 2010 call for topics of la Fundació La Marató de TV3. Acquired spinal cord and brain injuries]
2011	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[ChondroCelect® in patients with knee cartilage injury]
2011	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Corifollitropin alfa (Elonva®) for controlled ovarian stimulation in assisted human reproductive techniques]
2011	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Criteria for indication and surgical treatment in Parkinson´s disease and epilepsy]
2011	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Dabigatran etexilate for the prevention of stroke or systemic embolism in patients with non-vascular atrial fibrillation]
2011	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Real time continuous glucose monitoring systems]
2011	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Shoulder pain: appropriateness use of diagnostic imaging tests]
2011	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Telephone-based counselling and home care as strategies to reduce the frequentation rate to hospital emergencies services: a review]
2011	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	[Unplanned hospital readmissions in Catalonia]
2011	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Fiducial markers for improving treatment margins in radiotherapy for prostate cancer
2011	Technology Assessment Unit of the McGill University Health Centre (MUHC)	Use of the VerifyNow point of care test to detect nonresponsiveness to clopidogrel and aspirin
2011	Andalusian Health Technology Assessment Area (AETSA)	[Effectiveness and safety of inverted shoulder prosthesis for arthropathy of the rotator cuff: systematic review of the literature and appropriateness criteria]
2011	Andalusian Health Technology Assessment Area (AETSA)	[Paediatric triage systems in hospital emergency department: reliability and validity]
2011	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Ventilation systems in operating rooms a health technology assessment]
2011	Danish Centre for Evaluation and Health Technology Assessment (DACEHTA)	[Wound treatment in the patient's own home by collaboration between hospital and home care: a health technology assessment]
2011	Health Technology and Policy Unit (HTPU)	Middle ear implants for the treatment of hearing loss
2011	Health Technology and Policy Unit (HTPU)	Photodynamic therapy for skin cancer & pre-cancerous skin conditions
2011	Agency for Healthcare Research and Quality (AHRQ)	Screening and treatment of subclinical hypothyroidism or hyperthyroidism
2011	Agency for Healthcare Research and Quality (AHRQ)	Role of active surveillance in the management of men with localized prostate cancer
2011	Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS )	[Evaluation of multiple technologies for chronic wounds and burns]
2011	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Cost-utility analysis of the introduction of universal infant rotavirus vaccination in Spain]
2011	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Safety and efficacy of metformin in improving clinical, hormonal and metabolic features of polycystic ovary syndrome. Systematic review and meta-analysis ]
2011	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	A framework for science advice on health: principles and guidelines
2011	Andalusian Health Technology Assessment Area (AETSA)	[Prenatal screening for aneuploidy using free fetal DNA in maternal blood. Systematic review of the literature.]
2011	Andalusian Health Technology Assessment Area (AETSA)	[Efficacy and safety of active immunotherapy in HIV-infected adults. Therapeutic vaccines against HIV.]
2011	Scottish Health Technologies Group (SHTG)	Transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis in adults
2011	Scottish Health Technologies Group (SHTG)	What is the clinical and cost effectiveness of the ThinPrep imager® (HologicTM, Inc) for assisted cervical cytology compared with manual reading of liquid based cytology slides?
2011	Scottish Health Technologies Group (SHTG)	The clinical and cost effectiveness of the use of brachytherapy to treat breast cancer
2011	Scottish Health Technologies Group (SHTG)	What is the evidence base for the use of orthopaedic spinal surgery for mechanical low back pain or degenerative spondylolisthesis?
2011	Scottish Health Technologies Group (SHTG)	The clinical and cost effectiveness of the use of brachytherapy to treat localised prostate cancer
2011	Scottish Health Technologies Group (SHTG)	Transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis in adults. This evidence note updates evidence note 33 published in March 2011
2011	Scottish Health Technologies Group (SHTG)	The clinical and cost effectiveness of long-term ventricular assist devices (VADs) as a bridge-to-transplant in adults
2011	Scottish Health Technologies Group (SHTG)	Is radiofrequency ablation treatment a clinically and cost effective treatment to be offered to people with renal cancer in NHSScotland?
2011	NIHR Health Technology Assessment programme	Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction
2011	Agenzia nazionale per i servizi sanitari regionali (Agenas)	HIFU for the treatment of prostate cancer
2011	Agenzia nazionale per i servizi sanitari regionali (Agenas)	Systematic review of the methodological instruments used in Health Technology Assessment
2011	Agenzia nazionale per i servizi sanitari regionali (Agenas)	Systematic review of economic evaluation on the use of PET-CT for cancer staging
2011	Agenzia nazionale per i servizi sanitari regionali (Agenas)	[Consultation on the spread of tele-assistance for the management of the patient in post-stroke rehabilitation]
2011	National Evidence-based Healthcare Collaborating Agency (NECA)	[Effects of glucosamine in patients with osteoarthritis]
2011	Agency for Healthcare Research and Quality (AHRQ)	Treatments for localized prostate cancer: systematic review to update the 2002 U.S. Preventive Services Task Force Recommendation.
2011	Institute for Clinical Effectiveness and Health Policy (IECS)	[Usefulness of the bilateral cochlear implant in children]
2011	Institute for Clinical Effectiveness and Health Policy (IECS)	[Dabigatran for the prevention of ischemic stroke in patients with acute or chronic atrial fibrillation]
2011	Institute for Clinical Effectiveness and Health Policy (IECS)	[Usefulness of urea breath test for helicobacter pylori detection]
2011	Institute for Clinical Effectiveness and Health Policy (IECS)	[Pascal laser use in the treatment of retinal pathology]
2011	Institute for Clinical Effectiveness and Health Policy (IECS)	[Carotid echo doppler for plaque area measurement in cardiovascular risk stratification]
2011	Institute for Clinical Effectiveness and Health Policy (IECS)	[Usefulness of COL4A1 gene sequencing]
2011	Institute for Clinical Effectiveness and Health Policy (IECS)	[Usefulness of a specific intra-necrotic interventional technique for the diabetic Foot]
2011	Institute for Clinical Effectiveness and Health Policy (IECS)	[Pro-BNP peptide in the diagnosis and prognosis of heart failure]
2011	Institute for Clinical Effectiveness and Health Policy (IECS)	[Treatment of benign prostatic hypertrophy - Barreiro method]
2011	Institute for Clinical Effectiveness and Health Policy (IECS)	[Intensity modulated radiation therapy for three dimensional breast cancer]
2011	Institute for Clinical Effectiveness and Health Policy (IECS)	[Botulinum toxin for the treatment of headache]
2011	Institute for Clinical Effectiveness and Health Policy (IECS)	[Virtual hysterosalpingograghy to evaluate the uterus and tubes patency]
2011	National Evidence-based Healthcare Collaborating Agency (NECA)	[A study on the evaluation standards of osteoporosis in Korea]
2011	National Evidence-based Healthcare Collaborating Agency (NECA)	[A study on the factors influencing adherence to antidepressant therapies and the cost-effectiveness of antidepressant therapies in Korea]
2011	National Evidence-based Healthcare Collaborating Agency (NECA)	[Long-term safety and stability of refractive surgeries in myopia]
2011	National Evidence-based Healthcare Collaborating Agency (NECA)	[Burden of irritable bowel syndrome in Korea]
2011	National Evidence-based Healthcare Collaborating Agency (NECA)	[A study on current issues of hearing aid use in Korean patients with hearing loss]
2011	National Evidence-based Healthcare Collaborating Agency (NECA)	[A health technology assessment of the effectiveness and safety of robot surgery]